Yes, Spiriva is a LAMA, which stands for long-acting muscarinic antagonist. It’s one of the most widely prescribed inhalers in this drug class, used once daily to keep airways open in people with COPD and, in its Respimat form, asthma. The active ingredient is tiotropium bromide.
What LAMA Actually Means
A LAMA is a type of bronchodilator that works by blocking muscarinic receptors in the smooth muscle surrounding your airways. When a chemical messenger called acetylcholine binds to those receptors, the muscles tighten and your airways narrow. LAMAs prevent that from happening, keeping the airways relaxed and open for an extended period, typically 24 hours or longer.
The “long-acting” part is what separates LAMAs from older, short-acting anticholinergic inhalers like ipratropium, which wear off in a few hours. Tiotropium clings to the key receptor (called M3) for roughly 30 hours, which is why one dose a day is enough. It also releases from a different receptor type (M2) much faster, within about 3 hours. That matters because blocking M2 for too long can cause unwanted effects, so the selectivity of tiotropium is part of what makes it effective and well tolerated.
How Spiriva Differs From a LABA
You’ll often see LAMAs compared to LABAs (long-acting beta-agonists), which are the other main class of long-acting bronchodilator. Both keep airways open, but through completely different pathways. LABAs stimulate receptors that actively relax airway muscles. LAMAs block the signal that causes those muscles to tighten in the first place.
In practice, this creates some meaningful differences. LABAs tend to be slightly better at relieving day-to-day symptoms and improving quality of life. LAMAs, on the other hand, are more effective at reducing flare-ups (exacerbations) in COPD, likely through mechanisms beyond simple bronchodilation. Many people end up using both classes together, and combination LABA/LAMA inhalers have been shown to improve lung function more than either class alone.
What Spiriva Is Approved For
Spiriva is a maintenance inhaler, not a rescue inhaler. It’s designed for daily use to prevent symptoms, not to relieve sudden breathing difficulty. For COPD, it comes in two delivery systems: the HandiHaler, which uses dry powder capsules containing 18 mcg of tiotropium, and the Respimat, a soft-mist inhaler delivering 5 mcg. Despite the different doses, both deliver a similar amount of medication to the body.
As of 2020, tiotropium (via Respimat) is the only LAMA approved in the United States for treating asthma. It’s typically added on top of other controller medications when asthma isn’t well managed with an inhaled corticosteroid alone.
Common Side Effects
Because tiotropium dries up secretions as part of how it works, the most noticeable side effect for many people is dry mouth. Other commonly reported effects include sore throat, sinus inflammation, cough, bronchitis, and headaches.
Spiriva should not be used by anyone with narrow-angle glaucoma, as it can raise pressure inside the eye. People with an enlarged prostate or bladder obstruction should use it cautiously, since blocking muscarinic receptors can worsen urinary retention. It’s also contraindicated if you have a known allergy to tiotropium, ipratropium, or atropine, due to the risk of a severe allergic reaction.